These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21174537)

  • 1. Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?
    Davidson A; Gelmon K
    Future Oncol; 2011 Jan; 7(1):37-55. PubMed ID: 21174537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of anthracyclines in the treatment of early breast cancer.
    Greene J; Hennessy B
    J Oncol Pharm Pract; 2015 Jun; 21(3):201-12. PubMed ID: 24769570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands.
    van Herk-Sukel MP; van de Poll-Franse LV; Creemers GJ; Lemmens VE; van der Linden PD; Herings RM; Coebergh JW; Voogd AC
    Breast J; 2013; 19(4):394-401. PubMed ID: 23663128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
    Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.
    Pal SK; Childs BH; Pegram M
    Breast Cancer Res Treat; 2010 Jan; 119(1):25-32. PubMed ID: 19795206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].
    Belkacémi Y; Laharie-Mineur H; Gligorov J; Azria D
    Cancer Radiother; 2007 Sep; 11(5):266-75. PubMed ID: 17644449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer.
    Tang SC
    Cancer Invest; 2009 Feb; 27(2):206-14. PubMed ID: 19235594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of non-anthracycline regimens in early stage breast cancer in Australia.
    de Boer RH; Chan A; Tran B; Wilcken N
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):4-10. PubMed ID: 21332644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.
    Tang SC
    Cancer Invest; 2009 Jun; 27(5):489-95. PubMed ID: 19479486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the use of anthracyclines in older patients with breast cancer.
    Morris PG; Fornier MN
    Crit Rev Oncol Hematol; 2011 Feb; 77(2):131-41. PubMed ID: 20227291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab].
    Ito Y; Kobayashi K
    Gan To Kagaku Ryoho; 2009 May; 36(5):726-9. PubMed ID: 19461171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
    Jasra S; Anampa J
    Curr Treat Options Oncol; 2018 May; 19(6):30. PubMed ID: 29752560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
    J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in systemic adjuvant therapy of early-stage breast cancer.
    Gradishar WJ; O'Regan RM
    Int J Clin Oncol; 2003 Aug; 8(4):239-47. PubMed ID: 12955580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Popat S; Smith IE
    Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Role of adjuvant chemotherapy in the choice of chemotherapeutic treatment of metastatic breast cancer].
    Lopez M; Di Lauro L; Viola G; Conti F; Foggi P; Vici P
    Clin Ter; 2009; 160(6):489-97. PubMed ID: 20198293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.